Perioperative thromboprophylaxis in severely obese patients undergoing bariatric surgery: insights from a French national survey

Moulin, P; Dutour, Anne; Ancel, Patricia; Morange, Pierre‐Emmanuel; Bège, Thierry; Ziegler, O.; Berdah, Stéphane; Frère, Corinne; Gaborit, Bénédicte

doi:10.1016/j.soard.2016.08.497

Cited by 20 publications

(9 citation statements)

References 26 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…There is wide variation in bariatric surgery practice, particularly in terms of treatment duration and dose adjustment [ 229 , 230 ], and there is paucity of the literature for high-quality studies to inform clinical practice [ 231 ].…”

Section: Results: Evidence Base and Recommendationsmentioning

confidence: 99%

Guidelines for Perioperative Care in Bariatric Surgery: Enhanced Recovery After Surgery (ERAS) Society Recommendations: A 2021 Update

et al. 2022

View full text Add to dashboard Cite

Background This is the second updated Enhanced Recovery After Surgery (ERAS®) Society guideline, presenting a consensus for optimal perioperative care in bariatric surgery and providing recommendations for each ERAS item within the ERAS® protocol. Methods A principal literature search was performed utilizing the Pubmed, EMBASE, Cochrane databases and ClinicalTrials.gov through December 2020, with particular attention paid to meta-analyses, randomized controlled trials and large prospective cohort studies. Selected studies were examined, reviewed and graded according to the Grading of Recommendations, Assessment, Development and Evaluation (GRADE) system. After critical appraisal of these studies, the group of authors reached consensus regarding recommendations. Results The quality of evidence for many ERAS interventions remains relatively low in a bariatric setting and evidence-based practices may need to be extrapolated from other surgeries. Conclusion A comprehensive, updated evidence-based consensus was reached and is presented in this review by the ERAS® Society.

show abstract

Section: Results: Evidence Base and Recommendationsmentioning

confidence: 99%

Guidelines for Perioperative Care in Bariatric Surgery: Enhanced Recovery After Surgery (ERAS) Society Recommendations: A 2021 Update

et al. 2022

View full text Add to dashboard Cite

show abstract

“…3,4,5 We recently took advantage of the wellorganized French health care system for obesity treatment in the 37 Obesity Specialized Care Centres (CSO), to highlight this wide heterogeneity in pharmacologic prophylaxis dosing regimens and duration. Since these centers are all accredited by ministry of health, specialized in the coordination, medical and surgical care of the most severe cases of obesity (highest level of care), our results reflect well these uncertainities 6 , and suggest that there is still much to do in this regard.…”

Section: To the Editorsupporting

confidence: 65%

Pharmacologic Venous Thromboprophylaxis After Bariatric Surgery: Burning Questions Regarding Doses, Duration, and Strategy

Gaborit¹,

Aron‐Wisnewsky²,

Salem³

et al. 2018

Annals of Surgery

Self Cite

View full text Add to dashboard Cite

“…There is an urgent need for new data on heparin regimens (both LMWH and UFH) for prophylaxis and treatment of extremely obese patients, given also their high underlying VTE risk. 215 In view of the limited published data for many antithrombotic agents in relation to extremes of BW, the following are the specific proposals of this Working Group:…”

Section: Summary Proposals and Future Workmentioning

confidence: 99%

Antithrombotic therapy and body mass: an expert position paper of the ESC Working Group on Thrombosis

Rocca

Fox

Ajjan

et al. 2018

European Heart Journal

120

View full text Add to dashboard Cite

Increasing prevalence of cardiovascular disease and new evidence on the effects of antithrombotic therapies have expanded the use of antiplatelet and anticoagulant drugs. In addition, extremely low and high body weights have become more common due to frailty associated with ageing and to the global epidemic of obesity, 'globesity', respectively. These extreme body weights affect cardiovascular risk, including mortality, as well as the pharmacokinetics and safety profiles of antithrombotic drugs, some of which have a relatively narrow therapeutic window.The ESC Working Group on Thrombosis therefore assembled a task group to examine the key issues related to this topic and to address the question of whether modified antithrombotic management strategies are required for patients at the extremes of body weight. Greater focus is directed toward to obesity, given its higher prevalence among patients with cardiovascular disease and its associated complexities in terms of pharmacology and pathophysiology.Further research is warranted to optimize antithrombotic therapy in underweight as well as in different classes of obese patients, to guide dosing, dose-adjustment and/or reference intervals, and to establish whether the balance of benefits and risks of antithrombotic drugs can be improved.

show abstract

Perioperative thromboprophylaxis in severely obese patients undergoing bariatric surgery: insights from a French national survey

Cited by 20 publications

References 26 publications

Guidelines for Perioperative Care in Bariatric Surgery: Enhanced Recovery After Surgery (ERAS) Society Recommendations: A 2021 Update

Guidelines for Perioperative Care in Bariatric Surgery: Enhanced Recovery After Surgery (ERAS) Society Recommendations: A 2021 Update

Pharmacologic Venous Thromboprophylaxis After Bariatric Surgery: Burning Questions Regarding Doses, Duration, and Strategy

Antithrombotic therapy and body mass: an expert position paper of the ESC Working Group on Thrombosis

Contact Info

Product

Resources

About